🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Destiny-Breast-09 will likely establish a new first-line therapy for HER2+ MBC. Here are my considerations going into #ASCO25 Patient population considerations: 1) De novo patients (capped at 50%): these patients are more likely to respond durably and possibly even be cured in

📍For those who couldn’t make it to Chicago — here’s your front-row seat to a full day of groundbreaking breast cancer science at #ASCO25. From antibody-drug conjugates to AI, today’s oral sessions were packed with practice-changing potential. 🧵👇 #BreastCancer #Oncology

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

Presented at #ASCO25: In patients with advanced breast cancer, switching to camizestrant with a CDK4/6 inhibitor after ESR1-mutation detection (and before disease progression) led to significantly longer progression-free survival. Full SERENA-6 phase 3 trial results:

Original Article: Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer (INAVO120 trial) nej.md/3Zje7Vt #ASCO25 | ASCO

Original Article: Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer (VERITAC-2 phase 3 trial) nej.md/3ZoCL7g #ASCO25 | ASCO

🔬 AVATAR trial published(ER+/HER2– MBC on AI + CDK4/6i): In OPD, SABR delayed therapy change (mPFS 9.9 mo) 🔷 44% on same Rx at 12 mo 🔷 36% at 24 mo Some received SABR 2–3× for new oligoprogressions—modified endpoints may better reflect its value. ascopubs.org/doi/10.1200/OA…

So you've heard the practice changing exercise CHALLENGE trial! But what did that groundbreaking exercise program actually look like day-to-day? Let's explore the "Structured Exercise Program" based on info from their paper supplement on NEJM #ASCO2025 #ASCO25 1/10

x.com/i/article/1929…

Presented at #ASCO25: In the OASIS-4 phase 3 trial involving women taking endocrine therapy for HR-positive breast cancer, elinzanetant (a neurokinin-targeted therapy) significantly reduced the frequency of moderate-to-severe vasomotor symptoms. Full trial results:

.Sara Tolaney, MD, MPH shares interim results from the DESTINY-Breast09 study, comparing T-DXd + pertuzumab to the standard THP regimen for first-line treatment in HER2+ advanced breast cancer. #ASCO25

📌 Do We "Node" What to Do About the Axilla❓ Great discussion👏🏻 ✨Mediget Teshome, MD, FACS, MPH OncoAlert #OncoAlertAF #ASCO25

A blog post on CHALLENGE and why you should be prescribing exercise today #ASCO25 A 🧵 with some resources for you:

🚨 Wow! #ASCO25 ASCO was absolutely massive! 10 NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert

Funny how two of the more interesting pieces of data at #ASCO25 have little to do with extraneous medications per se, but rather the body’s circadian rhythm and physiology: 1: Exercise after surgery 2: Checkpoint inhibitors in the morning

For select breast cancer patients with complete response to neoadjuvant systemic therapy, radiotherapy alone without breast surgery may be feasible, as no tumor recurrences were observed at 5-year follow-up. ja.ma/4jxfdEA

Overview of ASCO 2025 Breast Cancer topics! #ASCO25 OncoAlert ASCO So many important topics.

In women with node-positive breast cancer whose nodes became free of disease after neoadjuvant therapy, regional nodal irradiation did not reduce breast cancer recurrence or improve survival. Full results from a phase 3 trial: nej.md/4dM6LjD

🗨️ “Vaccines have done more to improve public health than any other medical intervention.” A new Viewpoint focuses on cancer vaccines and the future of immunotherapy—analysing trials, different vaccine approaches, and how the next generation of cancer vaccines can help improve

This will be a great session...emerging evidence for RT for new indications 👇👇👇